250 related articles for article (PubMed ID: 23319695)
1. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
[No Abstract] [Full Text] [Related]
2. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
Frascaroli M; Di Cesare P
Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
4. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.
Sternberg CN; Hawkins RE; Wagstaff J; Salman P; Mardiak J; Barrios CH; Zarba JJ; Gladkov OA; Lee E; Szczylik C; McCann L; Rubin SD; Chen M; Davis ID
Eur J Cancer; 2013 Apr; 49(6):1287-96. PubMed ID: 23321547
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in renal carcinoma: a case of long-term effect with complete control of toxicity.
Conforti S; Ceniti S; Conforti L; Turano S; Minardi S; Palazzo S
Tumori; 2014; 100(6):e293-7. PubMed ID: 25688514
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib: therapeutic developments.
Limvorasak S; Posadas EM
Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
[TBL] [Abstract][Full Text] [Related]
7. [Another approach to targeted therapy of patients with metastatic renal carcinoma with progression in treatment with pazopanib:expert assessment by the Czech Cooperative Group for Metastatic Renal Carcinoma].
Büchler T; Finek J; Hájek J; Kocák I; Kubácková K; Lakomý R; Melichar B; Petruzelka L; Poprach A; Siffnerová M; Tomásek J; Vyzula R; Zemanová M;
Klin Onkol; 2013; 26(1):55-7. PubMed ID: 23607143
[No Abstract] [Full Text] [Related]
8. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
Bourdeanu L; Twardowski P; Pal SK
Clin J Oncol Nurs; 2011 Oct; 15(5):513-7. PubMed ID: 21951737
[TBL] [Abstract][Full Text] [Related]
9. Nursing considerations for patients receiving pazopanib for renal cell carcinoma.
Becze E
ONS Connect; 2012 Feb; 27(2):16-7. PubMed ID: 22375508
[No Abstract] [Full Text] [Related]
10. Pazopanib in renal cell carcinoma.
Sternberg CN
Clin Adv Hematol Oncol; 2010 Apr; 8(4):232-3. PubMed ID: 20505644
[No Abstract] [Full Text] [Related]
11. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacological sheet: pazopanib (Votrient), oral administration].
J Pharm Belg; 2011 Sep; (3):95-6. PubMed ID: 21995103
[No Abstract] [Full Text] [Related]
13. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
[TBL] [Abstract][Full Text] [Related]
14. Uveal metastasis and myasthenia gravis in a patient with recurrent renal cell carcinoma treated with pazopanib.
Jebb A; Hadden P; Broom RJ
Clin Genitourin Cancer; 2014 Aug; 12(4):e143-6. PubMed ID: 24656526
[No Abstract] [Full Text] [Related]
15. Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
Poprach A; Fiala O; Chloupkova R; Melichar B; Lakomy R; Petrakova K; Zemanova M; Kopeckova K; Slaby O; Studentova H; Kopecký J; Kiss I; Finek J; Dusek L; Buchler T
Anticancer Res; 2018 Jan; 38(1):449-456. PubMed ID: 29277808
[TBL] [Abstract][Full Text] [Related]
16. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.
Bonate PL; Suttle AB
Cancer Chemother Pharmacol; 2013 Jul; 72(1):231-40. PubMed ID: 23715625
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib.
Bukowski RM; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2010 Jan; 9(1):17-8. PubMed ID: 20043026
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic cardiac metastasis responding to pazopanib in a patient with renal cell carcinoma.
Behzadigohar R; Rosenthal MA; Tran B
Can J Urol; 2015 Jun; 22(3):7824-6. PubMed ID: 26068633
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
20. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
Nieto M; Borregaard J; Ersbøll J; ten Bosch GJ; van Zwieten-Boot B; Abadie E; Schellens JH; Pignatti F
Clin Cancer Res; 2011 Nov; 17(21):6608-14. PubMed ID: 21976546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
